Replimune Group Inc (REPL) Q2 2025 Earnings Report

Revenue: Not disclosed for QQ2 2025 (reported as null in the quarter); Gross Profit: Not disclosed; Operating Income: $(58.9) million with YoY improvement of 7.70% but QoQ decline of 2.70%; Net Income: $(53.1) million, YoY change reported as +11.64% and QoQ +1.33%; EPS: $(0.68) per share, YoY +24.44% and QoQ +12.82%; R&D Expense: $43.448 million; SG&A / Selling, General & Administrative: $15.468 million; Other (negative) expense: $(0.229) million; Interest: $1.969 million; D&A: $0.825 million; Net cash from operating activities: $(38.639) million; Free cash flow: $(40.723) million; Cash at end of period: $115.199 million; Total assets: $498.202 million; Total liabilities: $116.743 million; Total stockholders’ equity: $381.459 million; Current ratio: 10.11; Debt to total capitalization: 16.6%; Net debt: $(37.37) million.